Hyatt Regency Huntington Beach
Huntington Beach, CA
July 25-27, 2013

Overview

The goal of the 14^th International Lung Cancer Congress® is to provide physicians with practical information regarding tobacco cessation, lung cancer staging, the latest clinical data impacting the treatment of lung cancer, and novel agents and strategies that will shape the future of lung cancer therapy. The importance of personalized therapy will be emphasized, followed by other current topics of interest. State-of-the-art treatment for non–small-cell lung cancer (NSCLC) by stage, SCLC, and mesothelioma will be discussed. Didactic lectures and case-based panel discussions will be used to reinforce current standards and to present emerging clinical data. Panel discussions, multidisciplinary tumor boards, and question-and-answer sessions will allow the faculty to share their personal experiences and opinions on specific clinical scenarios and ongoing controversies in the treatment of lung cancer. Furthermore, a recurring session will highlight clinical research activity of Cooperative Groups in the United States, Europe, and Asia. This will provide invaluable education to the practicing physician to increase their knowledge and improve their performance in managing patients with lung cancer.

Target Audience

This educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer.  Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.

Topics

• International Strategies for Tobacco Cessation
• Impact and Application of the IASLC Staging Project
• ALK inhibitors
• MET inhibitors
• Emerging agents workshop
• Biomarkers for Personalized Lung Cancer Therapy / Next Generation Sequencing for Molecular Profiling
• Maintenance Therapy for Lung Cancer
• International Cooperative Group Update
• Case-based panel discussions and multidisciplinary tumor board

---

PER has chosen to partner with the International Association for the Study of Lung Cancer (IASLC) and the Bonnie J. Addario Lung Cancer Foundation (BJALCF) for the 14^th Annual International Lung Cancer Congress.
 
IASLC is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public.
 


BJALCF is the first international collaborative entity of its kind, raising over $6 million for Lung Cancer research. BJALCF’s focus is on projects promising progress through early detection, genetic testing, and drug discovery with patient-focused outcomes. Their ultimate goal is to increase the low survival rate of lung cancer by becoming the largest source of non-profit funding dedicated to turning lung cancer into a manageable chronic disease. Since 2008, BJALCF has sponsored a key-note address and provided overall support of the International Lung Cancer Congress.

Program Directors

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Roy S. Herbst, MD, PhD
Professor of Medicine and Pharmacology
Chief of Medical Oncology
Director, Thoracic Oncology Research Program
Associate Director for Translational Research
Translational Research Program
Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT 
 

Confirmed Faculty

Alex Adjei, MD, PhD
Professor and Chair
Department of Medicine
Katherine Anne Gioia Chair in Medicine
Roswell Park Cancer Center
Buffalo, NY
 
Hisao Asamura, MD
Chief of Thoracic Surgery
National Cancer Center
Tokyo, Japan
 
Paul Baas, MD, PhD
Professor of Thoracic Oncology
Department of Thoracic Oncology
The Netherlands Cancer Institute
Amsterdam, The Netherlands
 
Paul Bunn, Jr., MD
Professor, James Dudley Chair in Cancer Research
University of Colorado Denver
School of Medicine
Division of Medical Oncology
Aurora, CO
 
David Carbone, MD
Professor, Division of Medical Oncology
Director, Ohio State Comprehensive Cancer Center - James Cancer Hospital and Solove Research Center
Columbus, OH
 
Hak Choy, MD
Professor and Chairman
Nancy B. and Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research
Department of Radiology Oncology
The University of Texas Southwestern
Dallas, TX
 
Walter Curran, MD
Executive Director
Winship Cancer Institute of Emory University
Atlanta, GA
 
Laurie Gaspar, MD
Professor and Chair
Department of Radiation Oncology
Grohne Chair in Clinical Oncology
University of Colorado School of Medicine
Aurora, CO
 
Glenwood Goss, MD, FCPSA, FRCPC
Director of Clinical Research
The Ottawa Hospital Cancer Centre
Professor of Medicine, University of Ottawa
Chair, Thoracic Oncology Site Committee, NCIC CTG
Ottawa, Ontario, Canada
 
Dominique Grunewald, MD, PhD
Professor in Thoracic and Cardiovascular
Surgery Head, Department of Thoracic and Vascular Surgery
Hopital Tenon
University of Paris IV
Paris, France
 
Fred Hirsch, MD, PhD
Professor of Medical Oncology
University of Colorado School of Medicine
Aurora, CO
 
Karen Kelly, MD
Associate Director for Clinical Research
Professor of Medicine
UC Davis Comprehensive Cancer Center
Sacramento, CA
 
Corey Langer, MD, FACP
Professor of Medicine
Abramson Cancer Center
University of Pennsylvania
Philadelphia, PA
 
Primo Lara, Jr., MD
Professor of Medicine
Associate Director for Translational Research
UC Davis Comprehensive Cancer Center
Sacramento, CA
 
Tianhong Li, MD, PhD
Assistant Professor of Medicine
Co-Director, Phase I Program
UC Davis Cancer Center
Division of Hematology and Oncology
Sacramento, CA
 
Rogerio Lilenbaum, MD
Chief Medical Officer
Smilow Cancer Hospital at New Haven
New Haven, CT
 
Phillip Mack, PhD
Associate Adjunct Professor
Hematology/Oncology
Co-Leader Molecular Pharmacology
UC Davis Cancer Center
Sacramento, CA
 
Prof. Dr. Christian Manegold
Head of Interdisciplinary Thoracic Oncology in the Department of Surgery
University Medical Center Mannheim
Heidelberg University
Mannheim, Germany
 
Tetsuya Mitsudomi, MD
Vice Director and Chief
Department of Thoracic Surgery
Aichi Cancer Center Hospital
Nagoya, Japan
 
Tony Mok, MD
Professor, Department of Clinical Oncology
Chinese University of Hong Kong on Prince Wales Hospital
Hong Kong
 
Silvia Novello, MD
Thoracic Oncology Unit
Assistant Professor
University of Turin
Turin, Italy
 
Vassiliki Papadimitrakopoulou, MD
Professor, Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
 
Keunchil Park, MD, PhD
Professor, Division of Hematology/Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, Korea
 
Harvey Pass, MD
Stephen E. Banner Professor of Thoracic Oncology
NYU Cancer Center
New York, NY
 
Alan Sandler, MD
Professor of Medicine, Division of Hematology and Medical Oncology
DeArmond Chair for Clinical Research
Oregon Health and Science University
Portland, OR
 
Jill Siegfried, PhD
Professor
Department of Pharmacology and Chemical Biology
UPMC Endowed Chair for Lung Cancer Research
Hillman Cancer Center
Pittsburgh, PA
 
Rolf Stahel, MD
Clinic of Oncology
University Hospital Zuerich
Zuerich, Switzerland
 
Stephen Swisher, MD, FACS
Head, Division of Surgery ad interim
Professor and Chair
Department of Thoracic & Cardiovascular Surgery
Robert F. Fly Professorship of Surgical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston, TX
 
Everett Vokes, MD
John E. Ultmann Professor
Chairman, Department of Medicine
Physician-in-Chief
University of Chicago Medicine
Chicago, IL
 
Ken Y. Yoneda, MD
Professor of Clinical Internal Medicine
Division of Pulmonary and Critical Care
University of California, Davis Medical Center
Sacramento, CA

Agenda

• Thursday, July 25, 2013
• Friday, July 26, 2013
• Saturday, July 27, 2013

Thursday, July 25, 2013
6:00am	Registration and Breakfast
7:00am	Welcome and Introductions
7:05am	Pre-session Survey
State of the Art: Early-Stage Non-small Cell Lung Cancer (NSCLC)
7:15am	Optimal Application of Adjuvant Therapy in NSCLC
Optimizing NSCLC Staging: EBUS vs. Mediastinoscopy
7:35am	Endobronchial Ultrasound
7:55am	Mediastinoscopy
Surgical Resection vs. SBRT in Patients with NSCLC and Poor Pulmonary Function
8:15am	Surgical Resection
8:30am	Stereotactic Body Radiotherapy
8:50am	Role of the Pulmonologists in Diagnosis and Treatment Selection for Lung Cancer
9:15am	TBD
9:35am	Break
State of the Art in Combined Modality Therapy for NSCLC
10:00am	State of the Art: Multimodality Therapy
10:25am	Surgical Approaches to Locally Advanced NSCLC
10:50am	Optimizing the Dose and Schedule of Radiation Therapy in Stage III NSCLC
11:15am	TBD
11:40am	Integration and Targeted Agents Into Combined Modality Therapy for NSCLC
12:05pm	Post-session Survey
12:20pm	Case Based Panel Discussion: Combined Modality Therapy
12:30pm	Poster Discussant 1
12:45pm	LUNCH - Non-CME events or lunch on own
Workshop 1: Multidisciplinary Tumor Board
2:00pm	1. Surgical Case 2. Radiation Therapy Case 3. Pulmonary Case 4. Standard of Care Case
3:00pm	Adjournment
4:30pm	Welcome Reception in the Exhibit Hall
Friday, July 26, 2013
6:00am	Registration and Breakfast
7:00am	Welcome and Introductions
7:05am	Pre-session Survey
State of the Art Treatment of Advanced Lung Cancer
7:15am	Keynote: State of the Art: Lung Cancer
7:40am	ALK Inhibitors
8:05am	c-Met Inhibitors
8:30am	Antiangiogenic Agents
8:55am	Immunotherapy in Lung Cancer
9:20am	Incorporating Next Generation Sequencing for Molecular Profiling: Future Implications for Treatment
9:45am	Case Based Panel Discussion: Advanced NSCLC
10:05am	Break
Sixth Annual Addario Foundation Keynote Lecture
10:30am	Lung Cancer Management
Personalized Medicine for Mesothelioma and SCLC
11:00am	Mesothelioma
11:25am	Current Approaches for LD-SCLC
11:50am	How I Treat: ED-SCLC
12:20pm	Post-session Survey
12:25pm	Panel Discussion: Personalized Medicine for Mesothelioma and SCLC
12:45pm	Poster Discussant 2
12:55pm	LUNCH - Non-CME events or lunch on own
Workshop 2: The Next Generation of Agents for Lung Cancer
2:10pm	New Targets for Lung Cancer: Lessons Learned from the TCGA and Synthetic Lethal Screens
2:25pm	Targeting the PI3K/AKT Axis: Picking a Winner
2:40pm	Approaches tto Inhibiting bFGFR - Are They Ready for Primetime
2:55pm	PARP Inhibitors in Lung Cancer, Molecular Predictors and Combination Therapy
3:10pm	Break
3:35pm	MEK Inhibition: What Progress Have We Made
3:50pm	Reversing Resistance to EGFR TKIs - Approaches in the Front Line and Refractory Setting
4:05pm	Targeting KRAS in Lung Cancer: Search for the Holy Grail
4:15pm	Adjourn
5:00pm	Non-CME Dinner Events
Saturday, July 27, 2013
6:00am	Registration and Breakfast
7:00am	Welcome and Introductions
7:05am	Pre-session Survey
Maintenance and Second-line Therapy in Advanced NSCLC Maintenance Therapy for Lung Cancer Debate
7:15am	Pro
7:30am	Con
7:50am	Approaches to Therapy of Metastatic NSCLC: Second-line and Beyond
8:15am	Post-session Survey
8:20am	Case Based Panel Discussion: Maintenance Therapy and Beyond
8:40am	Break
Cooperative Group Update - "A Rose By Any Other Name?"
9:05am	SPORE Update
9:25am	Europe
9:45am	Asia
10:05am	SWOG
10:25am	NGR Oncology
10:45am	NCI-Canada
11:05am	ECOG-ACRIN
11:25am	Alliance
11:45am	LUNCH - Non-CME events or lunch on own
Personalized Medicine for NSCLC
1:00pm	Pre-session Survey
1:05pm	Keynote: Individualized Therapy in Lung Cancer: Where are we in 2013?
1:30pm	Biomarkers for Personalized Lung Cancer Therapy
1:55pm	The Role of Molecular Diagnostics
2:20pm	Personalized Medicine for Advanced NSCLC in East Asia
2:45pm	Break
3:10pm	Master Protocol for Designs for Implementing Personalized Medicine
3:35pm	Optimizing Care for Special Populations in Lung Cancer (Women, Elderly, PS2)
4:00pm	Post-session Survey
4:05pm	Case Based Panel Discussion: Personalized Medicine
4:30pm	Adjourn

Accommodations

Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA 92648
Telephone: (714) 698-1234
Reservations: (888) 421-1442
Website
 
A limited block of rooms has been set aside at Hyatt Regency Huntington Beach at a run-of-house rate of $279 (single) and $295 (double) plus applicable state and local taxes.  A $20 Resort Fee is assessed. Rates and rooms are subject to availability at the time of the reservation.

To make a reservation, call (888) 421-1442. The deadline for making your hotel reservations is June 24, 2013. After that date, or in the event that the room block becomes full prior to the deadline, rooms are subject to availability, and the room rates may increase. When booking, please use Lung Cancer Congress to receive the discounted group rate.

Travel Arrangements
PER recommends that you make your reservations early to get the best seat options and lowest airfare available. The gateways to the Huntington Beach are Los Angeles International Airport (LAX), Orange County/John Wayne Airport (SNA), Long Beach Airport (LGB) and Ontario Airport (ONT).

PER’s travel partner, TraveLink, is available to assist in making travel arrangements.  Please call (866) 301-3011 and ask for Peter Carson (ext. 2034) or Darrell Roberts (ext. 5193). You can also e-mail your request to Peter Carson at pcarson@trvlnk.com.

Exhibitors

Exhibit at this year’s meeting and increase your visibility!

This year’s meeting offers great support opportunities to increase your visibility and exposure.

Our sponsorship packages provide outstanding recognition and increased awareness of your company’s products and services. Don’t miss this opportunity to reach this important target audience!

For additional details, contact:
Jill Goldberg, Director of Sponsorships for Intellisphere - Liaison to PER
Intellisphere, LLC  | Oncology Group
Phone: 609-716-7777
Cell: 215-208-2075
Email: jgoldberg@onclive.com
Web: http://www.onclive.com

Registration

Registration fees include continental breakfast, breaks, and e-syllabus materials.

4 Ways to Register

1. Online: Click here.
2. Fax:  Please complete the registration form and fax to (609) 257-0705 (credit cards only).
3. Phone: Please call (888) 949-0045 or (609) 378-3701 (credit cards only).
4. Mail a completed registration form along with a check made payable to:

Physicians' Education Resource® - ILC13
666 Plainsboro Road, Suite 356
Plainsboro, NJ  08536
 
Registration Fees

	Advanced	On-Site
Physicians	$699	$779
Fellows*	$399	$479
Nurses, PAs, Other Health Care Professionals	$599	$679
Industry**	$799	$879

 
*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount.

**INDUSTRY is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.
 
For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.
 
A cancellation fee of 25% will be assessed on refunds requested prior to June 25, 2013, and a 50% fee on refunds requested on June 26, 2013, through July 18, 2013. No refunds will be made after July 18, 2013. There is no charge for substitution.
 
In the event of a meeting cancellation, full refunds will be processed within 30 days of the cancellation date.

Physicians' Education Resource® fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC (PER) reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.    

By attending a PER conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image").  By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER.

Meeting information is accurate at the time of posting.

Photos from the 13th International Lung Cancer Congress®

---